Nonmyeloablative stem cell transplantation for myelodysplastic syndrome or acute myeloid leukemia in patients 60 years or older

Biology of Blood and Marrow Transplantation

Volumn 11, Issue 10, 2005, Pages 764-772

  Gupta, Vikas ^a   Daly, Andrew ^a   Lipton, Jeffrey H ^a   Hasegawa, Wanda ^a   Chun, Kathy ^b   Kamel Reid, Suzanne ^b   Tsang, Richard ^a   Yi, Qi Long ^a   Minden, Mark ^a   Messner, Hans ^a   Kiss, Thomas ^a  

^a PRINCESS MARGARET HOSPITAL   (Canada)

^b UNIVERSITY HEALTH NETWORK   (Canada)

Author keywords

AML; MDS; Nonmyeloablative; Older; Stem cell transplantation

Indexed keywords

ACICLOVIR; ANTIBIOTIC AGENT; CIPROFLOXACIN; COTRIMOXAZOLE; CYCLOSPORIN A; FLUDARABINE; GANCICLOVIR; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PENTAMIDINE; STEROID;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ALLOGENEIC PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; ANTIMICROBIAL THERAPY; ARTICLE; BACTERIAL INFECTION; CANCER MORTALITY; CANCER RELAPSE; CANCER SURVIVAL; CAUSE OF DEATH; CHIMERA; CLINICAL ARTICLE; CYTOMEGALOVIRUS INFECTION; DISEASE SEVERITY; FEMALE; FOLLOW UP; GRAFT VERSUS HOST REACTION; HERPES SIMPLEX; HERPES ZOSTER; HIGH RISK PATIENT; HLA MATCHING; HUMAN; KERATITIS; KIDNEY FAILURE; LOW ENERGY RADIATION; MALE; MUCOSA INFLAMMATION; MYCOSIS; MYELODYSPLASTIC SYNDROME; NONMYELOABLATIVE CONDITIONING; NONMYELOABLATIVE STEM CELL TRANSPLANTATION; OPTIC NERVE DISEASE; PNEUMOCYSTIS CARINII; SEPSIS; SURVIVAL RATE; SURVIVAL TIME; TREATMENT OUTCOME; VEIN OCCLUSION;

ACUTE DISEASE; AGED; FEMALE; GRAFT SURVIVAL; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HISTOCOMPATIBILITY TESTING; HUMANS; LEUKEMIA, MYELOID; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; OPPORTUNISTIC INFECTIONS; SIBLINGS; SURVIVAL ANALYSIS; TRANSPLANTATION CONDITIONING; VIDARABINE; WHOLE-BODY IRRADIATION;

EID: 26044469602     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2005.06.006     Document Type: Article

References (52)

1. R.M. Stone D.T. Berg S.L. George et al. Postremission therapy in older patients with de novo acute myeloid leukemia: A randomized trial comparing mitoxantrone and intermediate-dose cytarabine with standard-dose cytarabine Blood 98 2001 548-553
2. J.E. Anderson K.J. Kopecky C.L. Willman et al. Outcome after induction chemotherapy for older patients with acute myeloid leukemia is not improved with mitoxantrone and etoposide compared to cytarabine and daunorubicin: A Southwest Oncology Group study Blood 100 2002 3869-3876
3. J.E. Godwin K.J. Kopecky D.R. Head et al. A double-blind placebo-controlled trial of granulocyte colony-stimulating factor in elderly patients with previously untreated acute myeloid leukemia: A Southwest Oncology Group study (9031) Blood 91 1998 3607-3615
4. A.H. Goldstone A.K. Burnett K. Wheatley et al. Attempts to improve treatment outcomes in acute myeloid leukemia (AML) in older patients: the results of the United Kingdom Medical Research Council AML11 trial Blood 98 2001 1302-1311
5. V. Gupta K. Chun Q.L. Yi et al. Disease biology rather than age is the most important determinant of survival of patients ≥60 years with acute myeloid leukemia treated with uniform intensive therapy Cancer 103 2005 2082-2090
6. B. Lowenberg S. Suciu E. Archimbaud et al. Use of recombinant GM-CSF during and after remission induction chemotherapy in patients aged 61 years and older with acute myeloid leukemia: Final report of AML-11, a phase III randomized study of the Leukemia Cooperative Group of European Organisation for the Research and Treatment of Cancer and the Dutch Belgian Hemato-Oncology Cooperative Group Blood 90 1997 2952-2961
7. J.M. Rowe D. Neuberg W. Friedenberg et al. A phase 3 study of three induction regimens and of priming with GM-CSF in older adults with acute myeloid leukemia: A trial by the Eastern Cooperative Oncology Group Blood 103 2004 479-485
8. W. Hiddemann W. Kern C. Schoch et al. Management of acute myeloid leukemia in elderly patients J Clin Oncol 17 1999 3569-3576
9. S. Giralt Bone marrow transplant in myelodysplastic syndromes: New technologies, same questions Curr Hematol Rep 3 2004 165-172
10. M. Yanada K. Matsuo N. Emi T. Naoe Efficacy of allogeneic hematopoietic stem cell transplantation depends on cytogenetic risk for acute myeloid leukemia in first disease remission Cancer 103 2005 1652-1658
11. R. Chakraverty K. Peggs R. Chopra et al. Limiting transplantation-related mortality following unrelated donor stem cell transplantation by using a nonmyeloablative conditioning regimen Blood 99 2002 1071-1078
12. P. Corradini C. Tarella A. Olivieri et al. Reduced-intensity conditioning followed by allografting of hematopoietic cells can produce clinical and molecular remissions in patients with poor-risk hematologic malignancies Blood 99 2002 75-82
13. S. Giralt E. Estey M. Albitar et al. Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: Harnessing graft-versus-leukemia without myeloablative therapy Blood 89 1997 4531-4536
14. S. Slavin A. Nagler E. Naparstek et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases Blood 91 1998 756-763
15. R. Martino M.D. Caballero C. Canals et al. Allogeneic peripheral blood stem cell transplantation with reduced-intensity conditioning: Results of a prospective multicentre study Br J Haematol 115 2001 653-659
16. P.A. McSweeney D. Niederwieser J.A. Shizuru et al. Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects Blood 97 2001 3390-3400
17. F. Baron M.B. Maris B.M. Sandmaier et al. Graft-versus-tumor effects after allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning J Clin Oncol 23 2005 1993-2003
18. D.C. Taussig A.J. Davies J.D. Cavenagh et al. Durable remissions of myelodysplastic syndrome and acute myeloid leukemia after reduced-intensity allografting J Clin Oncol 21 2003 3060-3065
19. A.Y. Ho A. Pagliuca M. Kenyon et al. Reduced-intensity allogeneic hematopoietic stem cell transplantation for myelodysplastic syndrome and acute myeloid leukemia with multilineage dysplasia using fludarabine, busulphan, and alemtuzumab (FBC) conditioning Blood 104 2004 1616-1623
20. R.K. Malladi A.J. Peniket A.E. Norton et al. Favourable outcome for patients with myeloid disorders treated with fludarabine-melphalan reduced-intensity conditioning and allogeneic bone marrow stem cell transplantation without the use of T-lymphocyte-depleting antibodies Eur J Haematol 73 2004 85-92
21. T. Hamaki M. Kami S.W. Kim et al. Reduced-intensity stem cell transplantation from an HLA-identical sibling donor in patients with myeloid malignancies Bone Marrow Transplant 33 2004 891-900
22. M. Gomez-Nunez R. Martino M.D. Caballero et al. Elderly age and prior autologous transplantation have a deleterious effect on survival following allogeneic peripheral blood stem cell transplantation with reduced-intensity conditioning: Results from the Spanish multicenter prospective trial Bone Marrow Transplant 33 2004 477-482
23. H.G. Sayer M. Kroger J. Beyer et al. Reduced intensity conditioning for allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia: Disease status by marrow blasts is the strongest prognostic factor Bone Marrow Transplant 31 2003 1089-1095
24. U. Platzbecker G. Ehninger N. Schmitz M. Bornhauser Reduced-intensity conditioning followed by allogeneic hematopoietic cell transplantation in myeloid diseases Ann Hematol 82 2003 463-468
25. N. Kroger M. Bornhauser G. Ehninger et al. Allogeneic stem cell transplantation after a fludarabine/busulfan-based reduced-intensity conditioning in patients with myelodysplastic syndrome or secondary acute myeloid leukemia Ann Hematol 82 2003 336-342
26. L.C. Feinstein B.M. Sandmaier U. Hegenbart et al. Non-myeloablative allografting from human leucocyte antigen-identical sibling donors for treatment of acute myeloid leukaemia in first complete remission Br J Haematol 120 2003 281-288
27. R. Martino M.D. Caballero J.A. Simon et al. Evidence for a graft-versus-leukemia effect after allogeneic peripheral blood stem cell transplantation with reduced-intensity conditioning in acute myelogenous leukemia and myelodysplastic syndromes Blood 100 2002 2243-2245
28. M.Y. Shapira I.B. Resnick M. Bitan et al. Low transplant-related mortality with allogeneic stem cell transplantation in elderly patients Bone Marrow Transplant 34 2004 155-159
29. H. Bertz K. Potthoff J. Finke Allogeneic stem-cell transplantation from related and unrelated donors in older patients with myeloid leukemia J Clin Oncol 21 2003 1480-1484
30. P. Greenberg C. Cox M.M. LeBeau et al. International scoring system for evaluating prognosis in myelodysplastic syndromes Blood 89 1997 2079-2088
31. F. Nollet J. Billiet D. Selleslag A. Criel Standardisation of multiplex fluorescent short tandem repeat analysis for chimerism testing Bone Marrow Transplant 28 2001 511-518
32. H. Glucksberg R. Storb A. Fefer et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors Transplantation 18 1974 295-304
33. H.M. Shulman K.M. Sullivan P.L. Weiden et al. Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients Am J Med 69 1980 204-217
34. M.E. Flowers F. Traina B. Storer et al. Serious graft-versus-host disease after hematopoietic cell transplantation following nonmyeloablative conditioning Bone Marrow Transplant 35 2005 277-282
35. S.I. Bearman F.R. Appelbaum C.D. Buckner et al. Regimen-related toxicity in patients undergoing bone marrow transplantation J Clin Oncol 6 1988 1562-1568
36. E. Kaplan P. Meier Nonparametric estimation from incomplete observations J Am Stat Assoc 53 1958 457-481
37. T.A. Gooley W. Leisenring J. Crowley B.E. Storer Estimation of failure probabilities in the presence of competing risks: New representations of old estimators Stat Med 18 1999 695-706
38. H. Wallen T.A. Gooley H.J. Deeg et al. Ablative allogeneic hematopoietic cell transplantation in adults 60 years of age and older J Clin Oncol 23 2005 3439-3446
39. M. Mielcarek P.J. Martin W. Leisenring et al. Graft-versus-host disease after nonmyeloablative versus conventional hematopoietic stem cell transplantation Blood 102 2003 756-762
40. S.R. Solomon S. Mielke B.N. Savani et al. Selective depletion of alloreactive donor lymphocytes - a novel method to reduce the severity of graft-versus-host disease in older patients undergoing matched sibling donor stem cell transplantation Blood 106 2005 1123-1129
41. G.G. Wulf K.L. Luo M.A. Goodell M.K. Brenner Anti-CD45-mediated cytoreduction to facilitate allogeneic stem cell transplantation Blood 101 2003 2434-2439
42. A. Bacigalupo Antilymphocyte/thymocyte globulin for graft versus host disease prophylaxis: Efficacy and side effects Bone Marrow Transplant 35 2005 225-231
43. M. Mohty W. Jacot C. Faucher et al. Infectious complications following allogeneic HLA-identical sibling transplantation with antithymocyte globulin-based reduced intensity preparative regimen Leukemia 17 2003 2168-2177
44. E. Meijer A.W. Dekker H.M. Lokhorst et al. Low incidence of infectious complications after nonmyeloablative compared with myeloablative allogeneic stem cell transplantation Transpl Infect Dis 6 2004 171-178
45. A. Daly S. McAfee B. Dey et al. Nonmyeloablative bone marrow transplantation: Infectious complications in 65 recipients of HLA-identical and mismatched transplants Biol Blood Marrow Transplant 9 2003 373-382
46. T.L. Kiss H. Chang A. Daly et al. Bone marrow aspirates as part of routine donor assessment for allogeneic blood and marrow transplantation can reveal presence of occult hematological malignancies in otherwise asymptomatic individuals Bone Marrow Transplant 33 2004 855-858
47. V. Gupta Q.L. Yi J. Brandwein et al. The role of allogeneic bone marrow transplantation in adult patients below the age of 55 years with acute lymphoblastic leukemia in first complete remission: A donor vs no donor comparison Bone Marrow Transplant 33 2004 397-404
48. A. Spyridonidis H. Bertz G. Ihorst C. Grullich J. Finke Hematopoietic cell transplantation from unrelated donors as an effective therapy for older patients (> or = 60 years) with active myeloid malignancies Blood 105 2005 4147-4148
49. C.S. Cutler S.J. Lee P. Greenberg et al. A decision analysis of allogeneic bone marrow transplantation for the myelodysplastic syndromes: Delayed transplantation for low-risk myelodysplasia is associated with improved outcome Blood 104 2004 579-585
50. L.R. Silverman E.P. Demakos B.L. Peterson et al. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: A study of the Cancer and Leukemia Group B J Clin Oncol 20 2002 2429-2440
51. A.B. Kornblith J.E. Herndon II L.R. Silverman et al. Impact of azacytidine on the quality of life of patients with myelodysplastic syndrome treated in a randomized phase III trial: A Cancer and Leukemia Group B study J Clin Oncol 20 2002 2441-2452
52. J. van den Bosch M. Lubbert G. Verhoef P.W. Wijermans The effects of 5-aza-2′-deoxycytidine (Decitabine) on the platelet count in patients with intermediate and high-risk myelodysplastic syndromes Leuk Res 28 2004 785-790